Blood biomarkers for Alzheimer’s disease: guidance on appropriate testing from the Association of British Neurologists and Royal College of Psychiatrists
Practical Neurology · 22.10.2026 · pn-2026-005461
DOI: 10.1136/pn-2026-005461 ↗Kurz gefasst
Fachartikel in der Zeitschrift Practical Neurology, online erschienen am 22.10.2026. Verfasst von Haniah Habash-Bailey und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Barts Health NHS Trust, London, England, UK. Die Arbeit nennt 31 Literaturangaben.
Themen: Demenz
Abstract (Originalsprache)
Blood tests that reflect the presence of neuropathological change associated with Alzheimer’s disease are becoming more widely available and may lead to more timely, accurate and equitable Alzheimer’s disease diagnosis. We convened a panel of experts from the Association of British Neurologists’ Cognitive Advisory Group and the Royal College of Psychiatrists’ Faculty of Old Age Psychiatry to develop consensus on the appropriate use of blood biomarkers in the diagnosis of Alzheimer9s disease. This guidance outlines an approach to ensure that an appropriate test is used in the correct context and that the results are interpreted and communicated with appropriate nuance. In particular, it emphasises that testing should be performed only in the context of a comprehensive assessment where there is reasonable suspicion of Alzheimer’s disease on clinical grounds. This guidance will be reviewed annually and updated in response to emerging evidence.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Barts Health NHS Trust, London, England, UK.
- Old Age Psychiatry, Cumbria Northumberland Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, England, UK.
- Diagnostic Memory Clinic, East London NHS Foundation Trust, London, England, UK.
- Division of Psychiatry, University College London, London, England, UK.
- Wessex Neurological Centre, University Hospital Southampton NHS Foundation Trust, Southampton, England, UK.
- Dementia Research Centre, UCL Queen Square Institute of Neurology, London, UK.
Zitieren
APA
Habash-Bailey, H., Barber, R., Bass, N., Harris, M. J., Hazan, J., Keshavan, A., Lunn, M. P., Mead, S., Pennington, C., Street, D., Underwood, B. R., Schott, J. M., & Marshall, C. R. (2026). Blood biomarkers for Alzheimer’s disease: guidance on appropriate testing from the Association of British Neurologists and Royal College of Psychiatrists. Practical Neurology, pn-2026-005461. https://doi.org/10.1136/pn-2026-005461
Vancouver
Habash-Bailey H, Barber R, Bass N, Harris MJ, Hazan J, Keshavan A, et al. Blood biomarkers for Alzheimer’s disease: guidance on appropriate testing from the Association of British Neurologists and Royal College of Psychiatrists. Practical Neurology. 2026:pn-2026-005461. doi:10.1136/pn-2026-005461
BibTeX
@article{HabashBailey2026,
author = {Habash-Bailey, Haniah and Barber, Robert and Bass, Nicholas and Harris, Matthew J and Hazan, Jemma and Keshavan, Ashvini and Lunn, Michael Pt and Mead, Simon and Pennington, Catherine and Street, Duncan and Underwood, Ben R and Schott, Jonathan M and Marshall, Charles R},
title = {Blood biomarkers for Alzheimer’s disease: guidance on appropriate testing from the Association of British Neurologists and Royal College of Psychiatrists},
journal = {Practical Neurology},
year = {2026},
pages = {pn--2026--005461},
doi = {10.1136/pn-2026-005461}
}
EUVIMED